These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37935468)
21. Chemokine Receptor-Targeted Therapies: Special Case for CCR8. Moser B Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158783 [TBL] [Abstract][Full Text] [Related]
22. TNFR2-expressing CD4 He J; Li R; Chen Y; Hu Y; Chen X Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403 [TBL] [Abstract][Full Text] [Related]
23. CD4 Liu S; Tao Z; Lou J; Li R; Fu X; Xu J; Wang T; Zhang L; Shang W; Mao Y; Wang F J Transl Med; 2023 Nov; 21(1):803. PubMed ID: 37950246 [TBL] [Abstract][Full Text] [Related]
24. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4 Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787 [TBL] [Abstract][Full Text] [Related]
25. TNFR2: Role in Cancer Immunology and Immunotherapy. Yang Y; Islam MS; Hu Y; Chen X Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692 [TBL] [Abstract][Full Text] [Related]
26. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. Moatti A; Cohen JL Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661 [TBL] [Abstract][Full Text] [Related]
27. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4 He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606 [TBL] [Abstract][Full Text] [Related]
28. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4 Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829 [TBL] [Abstract][Full Text] [Related]
29. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229 [TBL] [Abstract][Full Text] [Related]
30. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063 [TBL] [Abstract][Full Text] [Related]
31. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4 He T; Liu S; Chen S; Ye J; Wu X; Bian Z; Chen X Front Immunol; 2018; 9():1556. PubMed ID: 30038619 [TBL] [Abstract][Full Text] [Related]
32. The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. Mohd Salim NH; Mussa A; Ahmed N; Ahmad S; Yean Yean C; Hassan R; Uskoković V; Mohamud R; Che Jalil NA Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672682 [TBL] [Abstract][Full Text] [Related]
33. Distepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4 Chen FY; Geng CA; Chou CK; Zheng JB; Yang Y; Wang YF; Li TZ; Li P; Chen JJ; Chen X Phytomedicine; 2022 Dec; 107():154482. PubMed ID: 36202057 [TBL] [Abstract][Full Text] [Related]
34. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway. Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D Front Immunol; 2018; 9():1274. PubMed ID: 29922294 [TBL] [Abstract][Full Text] [Related]
35. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering. Inoue M; Tsuji Y; Kashiwada A; Yokoyama A; Iwata A; Abe Y; Kamada H; Tsunoda SI Biochem Biophys Res Commun; 2024 Feb; 697():149498. PubMed ID: 38262291 [TBL] [Abstract][Full Text] [Related]
36. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563 [TBL] [Abstract][Full Text] [Related]
37. TNFR2: A Novel Target for Cancer Immunotherapy. Vanamee ÉS; Faustman DL Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004 [TBL] [Abstract][Full Text] [Related]
38. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model. Jing Q; Wan Q; Nie Y; Luo J; Zhang X; Zhu L; Gui H; Li L; Wang C; Chen S; Wang M; Yuan H; Lv H; Pan R; Jing Q; Nie Y Front Pharmacol; 2023; 14():1286061. PubMed ID: 38161697 [No Abstract] [Full Text] [Related]
39. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Chen X; Oppenheim JJ Curr Dir Autoimmun; 2010; 11():119-34. PubMed ID: 20173391 [TBL] [Abstract][Full Text] [Related]
40. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]